Videos

Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence. 

Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer. 

Jason Zhu, MD, discusses factors he considers when choosing treatment for patients with lymph node–positive prostate cancer after prostatectomy.

Attorneys Acacia Brush Perko, Esq, and Kenton H. Steele, Esq, provide an overview of malpractice claims.

Dr Judd Moul and colleagues discuss best practices for monitoring patients with prostate cancer after definitive therapy. 

Dr Raoul Concepcion leads a panel of experts in prostate cancer in setting the stage for case-based discussions of biochemical recurrence.

Ward's analysis includes a discussion of adjuvant radiotherapy versus early salvage radiotherapy.

“This paper shows that our efforts to reduce… opioid exposure in the postoperative setting is reducing new persistent opioid use,” says Matthew S. Lee, MD.

Michael Devitt, MD, discusses the choice between erdafitinib and enfortumab vedotin in previously treated urothelial carcinoma.

“This test requires just one millimeter of cancer on a biopsy on five consecutive slides,” says Eric A. Klein, MD.

Dr. Ronald S. Swerdloff says Jatenzo showed “no evidence of liver toxicity.”

Tagawa draws specific attention to the targeted radioligand therapy 177Lu-PSMA-617.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, discusses emerging strategies for overcoming resistance to second-generation antiandrogens in prostate cancer.

“We found that a remarkable percentage of patients were getting narcotics refills from non urologists,” said Jay Simhan, MD, FACS.

Leonard G. Gomella, MD, discusses questions that still need to be resolved with biomarkers for the diagnosis and management of patients with prostate cancer.

Dr. Primo Lara, Jr., executive associate dean for Cancer Programs, School of Medicine, at UC Davis Comprehensive Cancer Center, highlights the need for personalized medicine using multidisciplinary care for patients with renal cell carcinoma.

Scott T. Tagawa, MD, highlights pivotal research and next steps with the alpha particle–emitting radioactive therapeutic agent radium-223 in prostate cancer.

“As we suspected, the more work interfered with their freedom to use the restroom, the fewer times they urinated during the work day,” says W. Stuart Reynolds, MD, MPH, FACS.

Jatenzo is approved by the FDA as a testosterone replacement therapy for men with certain forms of hypogonadism.

Dr. Leonard G. Gomella discusses emerging biomarkers and the use of MRI for the early detection of prostate cancer.

Michael E. Hurwitz, MD, PhD, discusses how immune checkpoint inhibitors have transformed the first-line setting in advanced renal cell carcinoma.

“For now, the UMPIRE [study] protocol will continue to withhold prophylaxis in the newborn population,” says investigator M. Chad Wallis, MD, FACS.

Watch the on-demand video of Urology Times' March 2021 Around the Practice.

“The way I think about this test now is… more as a dichotomous score,” says Eric A. Klein, MD.

“It’s really fascinating how the field is expanding,” Klein says.

“The take-home message is that for the appropriate patient, each of [these] technologies works well,” says Richard K. Lee, MD, MBA.

“It’s an extremely useful tool,” says Jonathan D. Tward, MD, PhD, of the Prolaris test.